83 related articles for article (PubMed ID: 7548767)
1. Construction, expression and the characterization of t-PA mutants with increased plasma half-life and resistance to inhibition by PAI-1.
Liu S; Huang P; Huang C
Chin J Biotechnol; 1995; 11(1):17-25. PubMed ID: 7548767
[TBL] [Abstract][Full Text] [Related]
2. Construction, expression and characterization of tissue-type plasminogen activator mutants.
Liu S; Huang P; Huang C
Sci China B; 1995 Nov; 38(11):1341-8. PubMed ID: 8745532
[TBL] [Abstract][Full Text] [Related]
3. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
de Vries C; Veerman H; Nesheim ME; Pannekoek H
Thromb Haemost; 1991 Mar; 65(3):280-5. PubMed ID: 1904654
[TBL] [Abstract][Full Text] [Related]
4. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
Ikenaka Y; Yajima K; Yahara H; Maruyama H; Matsumoto K; Okada K; Ueshima S; Matsuo O
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):381-7. PubMed ID: 1330023
[TBL] [Abstract][Full Text] [Related]
5. Structure and function of human tissue-type plasminogen activator (t-PA).
van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H
J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031
[TBL] [Abstract][Full Text] [Related]
6. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
8. Fibrin affinity and clearance of t-PA deletion and substitution analogues.
Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E
Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro.
Shohet RV; Spitzer S; Madison EL; Bassel-Duby R; Gething MJ; Sambrook JF
Thromb Haemost; 1994 Jan; 71(1):124-8. PubMed ID: 8165630
[TBL] [Abstract][Full Text] [Related]
10. Serpin-resistant mutants of human tissue-type plasminogen activator.
Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF
Nature; 1989 Jun; 339(6227):721-4. PubMed ID: 2500599
[TBL] [Abstract][Full Text] [Related]
11. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
[TBL] [Abstract][Full Text] [Related]
12. [Expression and activity of tissue-type plasminogen activator mutant reteplase with deletion of PAI-1 binding sites].
Zhu MC; Zhan Z; Wang YJ; Liu CG; Shi Y; Cai Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Sep; 21(5):565-9. PubMed ID: 16143058
[TBL] [Abstract][Full Text] [Related]
13. The role of the finger domain of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in initiation and progression of thrombolysis.
Stringer HA; van Swieten P; Horrevoets AJ; Smilde A; Pannekoek H
Thromb Haemost; 1994 Dec; 72(6):900-5. PubMed ID: 7740461
[TBL] [Abstract][Full Text] [Related]
14. A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on in silico experiments.
Davami F; Sardari S; Majidzadeh-A K; Hemayatkar M; Barkhordari F; Enayati S; Adeli A; Mahboudi F
BMB Rep; 2011 Jan; 44(1):34-9. PubMed ID: 21266104
[TBL] [Abstract][Full Text] [Related]
15. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells.
Kuiper J; Otter M; Voorschuur AH; van Zonneveld AJ; Rijken DC; van Berkel TJ
Thromb Haemost; 1995 Nov; 74(5):1298-304. PubMed ID: 8607113
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
Lijnen HR; Wagner EF; Collen D
Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597
[TBL] [Abstract][Full Text] [Related]
18. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
Thromb Haemost; 1994 Dec; 72(6):893-9. PubMed ID: 7740460
[TBL] [Abstract][Full Text] [Related]
19. Effect of Tisseel on expression of tissue plasminogen activator and plasminogen activator inhibitor-1.
Diamond MP; Kruger M; Saed GM
Fertil Steril; 2004 Jun; 81(6):1657-64. PubMed ID: 15193491
[TBL] [Abstract][Full Text] [Related]
20. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
